Advancing Innovation Across Medical Technology Sectors
Stryker Corporation, under the leadership of CEO Kevin Lobo, pursued an aggressive acquisition strategy in 2024 to expand its portfolio and address critical healthcare needs. By balancing internal innovation with high-impact external growth, Stryker has reinforced its position as a global leader in medical technology.
Key Acquisitions in 2024
- Inari Medical (Announced January 2025)
- Focus: Catheter-based mechanical thrombectomy for vascular diseases.
- Value: $4.9 billion.
- Impact: Strengthens Stryker’s vascular health portfolio and complements its neurovascular business.
- Vertos Medical (Completed September 2024)
- Focus: Minimally invasive treatments for lumbar spinal stenosis.
- Impact: Expands Stryker’s interventional pain management offerings.
- NICO Corporation (Completed September 2024)
- Focus: Minimally invasive solutions for brain tumor removal and intracerebral hemorrhage treatment.
- Impact: Enhances Stryker’s neurotechnology portfolio.
- Care.ai (Completed September 2024)
- Focus: AI-powered virtual care and smart room technology.
- Impact: Addresses healthcare staffing shortages and advances connected care environments.
- 4WEB Medical Products (Completed September 2024)
- Focus: Platforms for osteotomy and ankle fusion procedures.
- Impact: Expands Stryker’s Foot & Ankle portfolio.
- MOLLI Surgical (Completed July 2024)
- Focus: Wire-free soft tissue localization for breast-conserving surgeries.
- Impact: Strengthens Stryker’s oncology surgery capabilities.
- Artelon (Completed July 2024)
- Focus: Soft tissue fixation products for reconstructive surgeries.
- Impact: Enhances sports medicine offerings.
- Serf SaS (Completed April 2024)
- Focus: Hip implant technologies like the Dual Mobility Cup.
- Impact: Addresses growing demand for innovative hip replacement solutions.
Stryker’s Offensive M&A Strategy
At DeviceTalks West 2024, Andy Pierce, President of MedSurg and Neurotechnology, emphasized Stryker’s proactive approach:
“We’re fighting off the front foot in an offensive posture, combining organic innovation with external growth.”
With over 60 acquisitions in a decade, Stryker allocates 7% of annual sales to R&D while leveraging external innovation to diversify its portfolio and address emerging healthcare challenges.
Stryker’s 2024 acquisitions demonstrate its commitment to innovation and leadership across neurotechnology, orthopedics, oncology surgery, healthcare IT, and pain management. By remaining offensively positioned, Stryker continues to deliver transformative solutions that address global healthcare needs.
Follow MEDWIRE.AI for updates on Stryker and other groundbreaking advancements in medical technology!
